Adam Hansard's most recent trade in Applied Therapeutics Inc was a trade of 48,871 Common Stock done at an average price of $5.4 . Disclosure was reported to the exchange on March 14, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 5.39 per share. | 14 Mar 2024 | 48,871 | 732,919 (3%) | 0% | 5.4 | 263,415 | Common Stock |
| Applied Therapeutics Inc | Hansard Adam | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2023 | 400,000 | 781,790 (4%) | 2% | 0 | Common Stock | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.97 per share. | 30 Nov 2023 | 965 | 381,790 (2%) | 0% | 2.0 | 1,901 | Common Stock |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 2.70 per share. | 27 Sep 2023 | 9,720 | 382,755 (2%) | 0% | 2.7 | 26,244 | Common Stock |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2023 | 300,000 | 392,475 (2%) | 1% | 0 | Common Stock | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 0.91 per share. | 11 Jan 2023 | 4,495 | 92,475 (0%) | 0% | 0.9 | 4,090 | Common Stock |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Aug 2022 | 104,665 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Aug 2022 | 104,665 | 104,665 | - | - | Employee Stock Option (Right to Buy) | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Aug 2022 | 50,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Aug 2022 | 50,000 | 50,000 | - | - | Employee Stock Option (Right to Buy) | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Aug 2022 | 32,339 | 32,339 | - | - | Employee Stock Option (Right to Buy) | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Aug 2022 | 32,339 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Aug 2022 | 21,100 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Aug 2022 | 21,100 | 21,100 | - | - | Employee Stock Option (Right to Buy) | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Aug 2022 | 21,100 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Aug 2022 | 21,100 | 21,100 | - | - | Employee Stock Option (Right to Buy) | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Apr 2022 | 50,000 | 50,000 | - | - | Employee Stock Option (Right to Buy) | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 31,700 | 96,970 (0%) | 0% | 0 | Common Stock | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 21,100 | 21,100 | - | - | Employee Stock Option (Right to Buy) | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 31,700 | 65,270 (0%) | 0% | 0 | Common Stock | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 21,100 | 21,100 | - | - | Employee Stock Option (Right to Buy) | |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 18.35 per share. | 26 May 2021 | 2,894 | 33,570 (0%) | 0% | 18.4 | 53,105 | Common Stock |
| Applied Therapeutics Inc | Adam Hansard | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2020 | 81,700 | 81,700 | - | - | Stock Option (Right to Buy) |